This study aimed to investigate the potential association between dietary live microbe intake and sarcopenia. Data from 5368 participants were gathered from the National Health and Nutrition Examination Survey (NHANES). Dietary information was assessed using a self-report questionnaire. The participants were categorized into low, medium, and high dietary live microbe groups. Sarcopenia was defined according to the National Institutes of Health (NIH) definition (appendicular skeletal muscle mass/body mass index <0.789 for men and <0.512 for women). Multivariate regression analysis and stratified analyses were performed. After adjusting for potential confounding factors, individuals in the high dietary live microbe group exhibited a lower prevalence of sarcopenia compared to those in the low dietary live microbe group. The adjusted odds ratio (with 95% confidence intervals) was 0.63 (0.44-0.89) (p for trend <0.05). Subgroup analyses indicated a potential difference in the impact of dietary live microbe intake on sarcopenia between individuals with and without diabetes (p for interaction = 0.094). Higher dietary live microbe intake was associated with a lower risk of sarcopenia.

Emerging evidence indicates that transfer RNA (tRNA)‐derived small RNAs (tsRNAs), originated from tRNA with high abundance RNA modifications, play an important role in many complex physiological and pathological processes. However, the biological functions and regulatory mechanisms of modified tsRNAs in cancer remain poorly understood. Here, it is screened for and confirmed the presence of a novel m⁷G‐modified tsRNA, m⁷G‐3′‐tiRNA Lys^TTT (mtiRL), in a variety of chemical carcinogenesis models by combining small RNA sequencing with an m⁷G small RNA‐modified chip. Moreover, it is found that mtiRL, catalyzed by the tRNA m⁷G‐modifying enzyme mettl1, promotes bladder cancer (BC) malignancy in vitro and in vivo. Mechanistically, mtiRL is found to specifically bind the oncoprotein Annexin A2 (ANXA2) to promote its Tyr24 phosphorylation by enhancing the interactions between ANXA2 and Yes proto‐oncogene 1 (Yes1), leading to ANXA2 activation and increased p‐ANXA2‐Y24 nuclear localization in BC cells. Together, these findings define a critical role for mtiRL and suggest that targeting this novel m⁷G‐modified tsRNA can be an efficient way for to treat BC.

The study explores older people's perceptions and experiences with mobile technology adoption in hospitals. Twenty nine older people were interviewed at a tertiary hospital in Guangzhou from June to December 2020. All the interviews were analyzed using thematic analysis. Older people are a diversified group. Various factors impact their readiness for technology use, including their educational level, age, past experiences, living arrangements, etc. The older people in this study in general expressed a great concern about using the new health technology and many encountered barriers to its successful adoption. Yet, the barriers and difficulties that they encountered are embedded in a changed social context in China. The findings above provide insights into the adoption of health technology, and tailored measures to facilitate older people's technology adoption are suggested.

A patient-reported outcome (PRO) constitutes information about symptom severity, disease state, and change from a previous measure that comes directly from patients.^1,2 PROs provide evidence for evaluating the disease status or changes during treatment.³ Rigorously captured PRO results of trials have substantial implications for pharmaceutical labeling claims,⁴ product reimbursement,³ and decision-making on medicine use,⁵ and may even be factors in health care policy.⁵ PROs have been widely used to understand the perspective of patients in randomized clinical trials⁵ and clinical practice⁶ and have several advantages, including being noninvasive, patient-centered, and easily accessed.⁷